EP2743264A1 — New crystalline form of cabazitaxel, process for the preparation and pharmaceutical compositions thereof
Assigned to Indena SpA · Expires 2014-06-18 · 12y expired
What this patent protects
The present invention relates to a new crystalline form of Cabazitaxel, herein designated as form G, obtained by crystallization of Cabazitaxel from acetonitrile or from mixtures of acetonitrile and water. The new crystalline form G of the invention is endowed with several advant…
USPTO Abstract
The present invention relates to a new crystalline form of Cabazitaxel, herein designated as form G, obtained by crystallization of Cabazitaxel from acetonitrile or from mixtures of acetonitrile and water. The new crystalline form G of the invention is endowed with several advantageous properties as compared to the previously disclosed forms of Cabazitaxel.
Drugs covered by this patent
- Jevtana Kit (cabazitaxel) · Accord Hlthcare
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.